论文部分内容阅读
为观察尿激酶天普洛欣，经静脉溶栓治疗老年急性心肌梗死的临床有效性及安全性，将４１例老年病人分成两组，治疗组２０例，对照组２１例，观察临床疗效、副作用及病死率等。结果显示，尿激酶组临床血管再通率为６０．０％，对照组为９．９％，差异显著（Ｐ＜０．０５）。５ｗｋ总病死率，尿激酶组为１５．０％，对照组２８．６％，两组相比差异显著（Ｐ＜０．０５），尿激酶组仅有轻度皮肤出血。结果提示尿激酶治疗老年心肌梗死安全有效。
To observe the clinical efficacy and safety of intravenous thrombolysis in the treatment of senile acute myocardial infarction, 41 elderly patients were divided into two groups: 20 cases in the treatment group and 21 cases in the control group. Clinical efficacy and side effects were observed And mortality and so on. The results showed that the rate of clinical vascular recanalization was 60.0% in the urokinase group and 9.9% in the control group, with significant difference (P <0.05). 5wk overall mortality, urokinase group 15.0%, control group 28.6%, significant difference between the two groups (P <0.05), urokinase group only mild skin hemorrhage. The results suggest that urokinase treatment of elderly myocardial infarction safe and effective.